Atlas Trials

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Clinical trial NCT06485271 · RECRUITING

Trial details

NCT number
NCT06485271
Sponsor
Changzhi People's Hospital Affiliated to Changzhi Medical College
Status
RECRUITING
Study type
OBSERVATIONAL
Gastric CancerRWSPD-1 Immunotherapy
Start date
2023-11-01
Primary completion
2025-10-01
Enrollment
504

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.